Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Interferon-β therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome.
Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort.
SJL mice exposed to cuprizone intoxication reveal strain and gender pattern differences in demyelination.
MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study.
TECFIDERA prescribing information
A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity.
Remyelination of the superior cerebellar peduncle in the mouse following demyelination induced by feeding cuprizone.
Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.
Multiple sclerosis in Hispanics: a study of clinical disease expression.
Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis.
Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone.
Demyelination and remyelination in anatomically distinct regions of the corpus callosum following cuprizone intoxication.
Sequential myelin protein expression during remyelination reveals fast and efficient repair after central nervous system demyelination.
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.
Masitinib mesylate application for conditional approval
T-helper 1-type immunity to trophoblast in women with recurrent spontaneous abortion.
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Effects of fumaric acids on cuprizone induced central nervous system de- and remyelination in the mouse.
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Effects of dimethyl fumarate on neuroprotection and immunomodulation.
Integrating Acupuncture Within a Wellness Intervention for Women With Multiple Sclerosis: A Feasibility Study.
Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
“Veterinary Medicines” page

Pages